1 / 21

In-situ Monitoring of Polymorph Crystallisation and Interconversion Solvent Dependence

In-situ Monitoring of Polymorph Crystallisation and Interconversion Solvent Dependence. N. Blagden 1 , A. C. Williams 1 , S. W. Booth 2 and C. R. Petts 2 . 1 School of Pharmacy, University of Bradford, UK. 2 Merck Sharp & Dohme, Hoddesdon, UK. Luciana De Matos 1. INTRODUCTION.

Download Presentation

In-situ Monitoring of Polymorph Crystallisation and Interconversion Solvent Dependence

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. In-situ Monitoring of Polymorph Crystallisation and Interconversion Solvent Dependence N. Blagden1, A. C. Williams1, S. W. Booth2 and C. R. Petts2. 1School of Pharmacy, University of Bradford, UK. 2Merck Sharp & Dohme, Hoddesdon, UK. Luciana De Matos1

  2. INTRODUCTION • Polymorph behaviour. • Crystallisation. • Molecular aggregation. • Nucleation. • Crystal growth. • Phase-interconversion.

  3. AIMS • Polymorph screening of model drug. • Monitor phase-interconversions in different environments. • Molecular organisation relationship: - Molecular aggregates vs. crystalline forms.

  4. COMPOUND SELECTION • Three reported polymorphs. Piracetam (2-oxo-pyrrolidineacetamide) Form III Form II Form I Piracetam polymorphs diffraction patterns.

  5. Small molecule with high functionality. COMPOUND SELECTION Piracetam (2-oxo-pyrrolidineacetamide)

  6. Therapeutic application: - Pioneer nootropic drug. - Cognition enhancer. - Dementia, Alzheimer's disease, etc. COMPOUND SELECTION Piracetam (2-oxo-pyrrolidineacetamide)

  7. POLYMORPH SCREENING • Quench-cooling crystallisation: • Methanol, 2-Propanol and Nitromethane. • Characterisation: • Microscopy. • Thermal gravimetric analysis. • Differential scanning calorimetry. • Powder X-ray diffraction. • Single crystal X-ray diffraction.

  8. POLYMORPH SCREENING

  9. POLYMORPH SCREENING • Form I crystals: - White irregular shape, unstable at 25° C. • Forms II & III: - Prismatic morphology, stable at 25° C. 120 µm Form I Form II Form III

  10. EDS-XRD Energy Dispersive Synchrotron X-Ray Diffraction: • Station 16.4 at Daresbury Laboratory of CCLRC, UK. • Initially non-saturated solutions. • Sequence of fixed time scans. • Temperature reduced over time.

  11. Stirrer at 300 rpm Temperature probe Crystalliser * View of stirrer blade showing 5° torsion “Plume” of crystals Temperature control unit linked to digital monitor Copper sleeve Insulated crystalliser holder Electric heating unit. Cooling unit. (50/50 glycol/water) Heating-cooling loop X-Ray beam passage EDS-XRD • EDS-XRD experimental protocol: * Blagden, N., Davey, R.J., Song, M., Quayle, M.J., Clark, S., Taylor, D. & Nield, A. (2002). J. CrystalGrowth & Design 3 (2), 197-201.

  12. No crystals Form I Teflon Form III EDS-XRD • Piracetam crystallisation in methanol :

  13. No crystals Form I Teflon Form II Form III EDS-XRD • Piracetam crystallisation in 2-propanol:

  14. No crystals Form I Teflon Form II Form III EDS-XRD • Piracetam crystallisation in nitromethane: Rel. intensity / counts

  15. RAMAN SPECTROSCOPY • Spectra collected: - At room temperature. - Non-saturated solutions. - Crystalline material. - Measured at 488, 785 and 1064 nm.

  16. RAMAN SPECTROSCOPY • 2-Propanol and nitromethane solutions: - Low concentration at room temperature. - Piracetam not observed in solution. • Methanol solution: - Piracetam molecular clusters observed. • Form I spectrum not obtained.

  17. RAMAN SPECTROSCOPY • Example of Raman spectra measured at 785 nm.

  18. CONCLUSIONS • Form I acts as an initial intermediate. • Piracetam polymorphs observed: - Methanol: Form I Form III. - 2-Propanol: Form I Form III Form II. - Nitromethane: Form I Form III Form II.

  19. CONCLUSIONS • Suggested lattice organisation of piracetam molecules in methanol. • Solution organisation of clusters does not reflect the ones observed in forms II or III. • Polymorph-specific clusters?

  20. ACKNOWLEDGEMENTS • School of Life Sciences, University of Bradford. • Merck Sharp & Dohme. • Erice Organising Committee. • Station 16.4 at Daresbury Laboratory CCLRC. • Prof. Roger Davey and group, UMIST. • Dr. Ian Scowen and Dr. Colin Seaton, University of Bradford.

  21. THANK YOU

More Related